Department of Anesthesiology, The First Affiliated Hospital of Dalian Medical University, No. 5 Longbin Road, Dalian, 116011, China.
Department of Neuroelectrophysiology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116011, China.
BMC Surg. 2021 May 27;21(1):266. doi: 10.1186/s12893-021-01262-8.
This study aimed to investigate the anesthetic effect of butorphanol with different doses in patients undergoing gastroscopy and colonoscopy.
480 patients undergoing gastroscopy and colonoscopy were recruited and randomly divided into four groups to receive different doses of butorphanol (Group A = 2.5 μg/kg, Group B = 5 μg/kg, Group C = 7.5 μg/kg and Group D = 10 μg/kg). Butorphanol was administered 5 min before propofol infusion. The primary outcome was the incidence of body movement. Secondary outcomes were postoperative recovery time, length of stay in the Post-Anesthesia Care Unit (PACU), the total dose of propofol, and the incidence of intraoperative hypoxemia, propofol injection pain, cough, postoperative nausea and vomiting, drowsiness, and dizziness.
The incidence of body movement and the dose of propofol in Group C and D were lower than those in Group A and B (P < 0.05). The incidence and intensity of propofol injection pain and the incidence of cough in Group B, C, and D were lower than those in Group A (P < 0.05). The length of stay in PACU and the incidence of postoperative drowsiness and dizziness were higher in Group D than in Group A, B, and C (P < 0.05).
Intravenous pre-injection of 7.5 μg/kg butorphanol with propofol can be the optimal dosage for patients undergoing gastroscopy and colonoscopy.
Trial registration: Chinese Clinical Trial Registry, ChiCTR2000031506. Registered 3 April 2020-Retrospectively registered, http://www.medresman.org.cn .
本研究旨在探讨不同剂量布托啡诺在接受胃镜和结肠镜检查的患者中的麻醉效果。
将 480 例接受胃镜和结肠镜检查的患者纳入研究，并随机分为四组，分别接受不同剂量的布托啡诺（A 组：2.5μg/kg；B 组：5μg/kg；C 组：7.5μg/kg；D 组：10μg/kg）。在丙泊酚输注前 5 分钟给予布托啡诺。主要结局为身体运动的发生率。次要结局为术后恢复时间、PACU 停留时间、丙泊酚总剂量以及术中低氧血症、丙泊酚注射疼痛、咳嗽、术后恶心呕吐、嗜睡和头晕的发生率。
C 组和 D 组的身体运动发生率和丙泊酚剂量均低于 A 组和 B 组（P<0.05）。B、C 和 D 组丙泊酚注射疼痛的发生率和强度以及咳嗽的发生率均低于 A 组（P<0.05）。D 组 PACU 停留时间以及术后嗜睡和头晕的发生率高于 A、B 和 C 组（P<0.05）。
静脉预注 7.5μg/kg 布托啡诺联合丙泊酚可为胃镜和结肠镜检查患者提供最佳剂量。
临床试验注册：中国临床试验注册中心，ChiCTR2000031506。注册日期：2020 年 4 月 3 日-回顾性注册，http://www.medresman.org.cn。
